In This Article:
When it comes to investing in pharmaceutical stocks, an intriguing area for future growth is gene editing. This is an exciting field that may provide a solution to some of our most vexing diseases, such as cancer and diabetes.
And in 2023, many companies are closer than ever to a solution. So, although I know that’s not how it works, it was interesting that when ChatGPT gave me a list of pharmaceutical stocks, it included several which have partnerships with gene editing companies.
It’s important to note that pure-play gene editing companies, such as CRISPR Technologies (NASDAQ:CRSP), carry significant risk. But being cautious doesn’t have to mean staying on the sidelines. It can simply be a matter of knowing what you own.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The companies that are in partnerships with these pure-play gene editing companies make it more likely that the promise of gene editing will result in commercially approved and available products. They’re also examples of the high potential pharma stocks you can consider for long-term growth.
Pfizer (PFE)
Source: Manuel Esteban / Shutterstock.com
For better or worse, Pfizer (NYSE:PFE) is synonymous with its Covid-19 vaccine. Many investors plowed into PFE stock in 2020. But many of those investors likely sold their positions as sales of the company’s Covid-19 vaccine Comirnaty and its antiviral Paxlovid are normalizing.
That has sent the stock down nearly 38% from its all-time high of $59.48 on December 17, 2021. The question that investors should consider is what is the outlook for PFE stock when considering investing in pharma stocks?
The answer may be 19. That’s the number of drug launches and label expansions the company has planned in the next year. The company also projects these drugs to generate $20 billion in sales by 2030. That would be about 20% of the total revenue the company generated in 2022.
Not all of these drugs will hit, of course. But Pfizer also recently acquired Seagen (NASDAQ:SGEN) for $43 billion. This will allow the company to expand its portfolio of oncology drugs. And it provides more opportunity for the company to deliver shareholder value.
The company is also expanding into other areas such as gene editing. In 2022, Pfizer announced a $1.3 billion partnership with Beam Therapeutics (NASDAQ:BEAM). The companies will use Beam’s “base editing” technology to make precise corrections to typographical errors in gene sequences.
And the best news of all is that Pfizer stock is objectively undervalued. It currently trades at just 7x earnings and has a dividend with a 4.5% yield.